what to do when tirzepatide stops working People Who Stopped Taking the Weight Loss Drug Regained Nearly Half the Weight They Lost why has tirzepatide stopped working

Avo AP, Agua-Doce I, Andrade A, Padua E

PHARMA & BIOTECH Driven by the rise of obesity and Type 2 diabetes worldwide, the GLP1 (known as Glucagon-Like Peptide-1) market has become one of the fastestgrowing segments in the pharmaceutical industry according to the WHO Global Obesity Facts in 2025

According to one study, the most common side effects are gastrointestinal issues, including: Nausea Vomiting Diarrhea Abdominal pain Rare, but more serious side effects can include allergic reactions, thyroid tumors, and pancreatitis (inflammation of the pancreas)

Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes and obesity, offering significant benefits in glycemic control and weight reduction